IL267172A - Compositions comprising methylphenidate-prodrugs, processes of making and using the same - Google Patents
Compositions comprising methylphenidate-prodrugs, processes of making and using the sameInfo
- Publication number
- IL267172A IL267172A IL267172A IL26717219A IL267172A IL 267172 A IL267172 A IL 267172A IL 267172 A IL267172 A IL 267172A IL 26717219 A IL26717219 A IL 26717219A IL 267172 A IL267172 A IL 267172A
- Authority
- IL
- Israel
- Prior art keywords
- methylphenidate
- prodrugs
- compositions
- processes
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662432675P | 2016-12-11 | 2016-12-11 | |
US201762519627P | 2017-06-14 | 2017-06-14 | |
US201762541695P | 2017-08-05 | 2017-08-05 | |
PCT/US2017/065482 WO2018107132A1 (en) | 2016-12-11 | 2017-12-09 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
IL267172A true IL267172A (en) | 2019-08-29 |
Family
ID=62491385
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL297652A IL297652A (en) | 2016-12-11 | 2017-12-09 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
IL267172A IL267172A (en) | 2016-12-11 | 2019-06-06 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL297652A IL297652A (en) | 2016-12-11 | 2017-12-09 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Country Status (17)
Country | Link |
---|---|
US (10) | US10584113B2 (en) |
EP (2) | EP3551619B1 (en) |
JP (1) | JP6963614B2 (en) |
KR (1) | KR102337138B1 (en) |
CN (1) | CN110234636B (en) |
AU (2) | AU2017371327B2 (en) |
BR (1) | BR112019011640B1 (en) |
CA (1) | CA3046486A1 (en) |
DK (1) | DK3551619T3 (en) |
FI (1) | FI3551619T3 (en) |
IL (2) | IL297652A (en) |
LT (1) | LT3551619T (en) |
MX (1) | MX2019006670A (en) |
NZ (1) | NZ754751A (en) |
RS (1) | RS65591B1 (en) |
WO (1) | WO2018107132A1 (en) |
ZA (1) | ZA201903928B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9653940B2 (en) | 2015-06-02 | 2017-05-16 | Voyetra Turtle Beach, Inc. | Headset wireless charging dock |
AU2017371327B2 (en) | 2016-12-11 | 2020-10-15 | Zevra Therapeutics, Inc. | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
WO2019241019A1 (en) * | 2018-06-15 | 2019-12-19 | Kempharm, Inc. | Serdexmethylphenidate conjugates, compositions and methods of use thereof |
US11136295B2 (en) * | 2018-10-29 | 2021-10-05 | Kempharm, Inc. | D-amphetamine compounds, compositions, and processes for making and using the same |
CN115666534A (en) * | 2020-02-29 | 2023-01-31 | 肯法姆股份有限公司 | Compositions comprising methylphenidate prodrugs, methods of making and using the same |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6622036B1 (en) | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
AU2114199A (en) | 1998-01-13 | 1999-08-02 | Trustees Of The University Of Pennsylvania, The | Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
CA2420569A1 (en) | 2000-08-28 | 2002-03-07 | Mel H. Epstein | Use of threo-methylphenidate compounds to enhance memory |
US20020132793A1 (en) | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
IL151251A0 (en) | 2002-08-14 | 2003-04-10 | Elta Systems Ltd | Parallel processing platform with synchronous system halt-resume |
WO2004080959A2 (en) | 2003-03-07 | 2004-09-23 | Isp Investments Inc. | Process for the preparation of dexmethylphenidate hydrochloride |
EP1644019B2 (en) * | 2003-05-29 | 2018-02-21 | Shire LLC | Abuse resistant amphetamine compounds |
US20060100243A1 (en) | 2004-10-22 | 2006-05-11 | Mark Froimowitz | Methylphenidate analogs and methods of use thereof |
US8163701B2 (en) | 2005-08-19 | 2012-04-24 | Signature Therapeutics, Inc. | Prodrugs of active agents |
RU2464977C2 (en) * | 2006-08-23 | 2012-10-27 | Тзе Юнивесити Оф Монтана | Method of reducing demage to nervous cells |
CA2672138A1 (en) | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
EP2125709A2 (en) | 2007-02-02 | 2009-12-02 | Colucid Pharmaceuticals, Inc. | Compounds that inhibit cholinesterase |
EP2109465B1 (en) | 2007-02-08 | 2012-04-11 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
CN101631768A (en) | 2007-03-15 | 2010-01-20 | 太阳医药高级研究有限公司 | Novel prodrugs |
RU2470021C2 (en) | 2007-05-23 | 2012-12-20 | Мерк Шарп Энд Домэ Корп. | Pyridyl-piperidine antagonists of orexin receptors |
WO2009035473A2 (en) | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
UA112654C2 (en) | 2011-07-28 | 2016-10-10 | Кемфарм Інк. | Methylphenidate-prodrugs, processes of making and using the same |
JP5952912B2 (en) | 2011-12-15 | 2016-07-13 | アルカーメス ファーマ アイルランド リミテッド | Prodrugs of secondary amine compounds |
US9088326B2 (en) | 2012-07-18 | 2015-07-21 | Rf Micro Devices, Inc. | Front end radio architecture having a split band arrangement with co-banding |
AU2017371327B2 (en) * | 2016-12-11 | 2020-10-15 | Zevra Therapeutics, Inc. | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
WO2018107131A1 (en) | 2016-12-11 | 2018-06-14 | Kempharm, Inc. | Methylphenidate-prodrugs, processes of making and using the same |
WO2019241019A1 (en) * | 2018-06-15 | 2019-12-19 | Kempharm, Inc. | Serdexmethylphenidate conjugates, compositions and methods of use thereof |
-
2017
- 2017-12-09 AU AU2017371327A patent/AU2017371327B2/en active Active
- 2017-12-09 RS RS20240637A patent/RS65591B1/en unknown
- 2017-12-09 JP JP2019530444A patent/JP6963614B2/en active Active
- 2017-12-09 MX MX2019006670A patent/MX2019006670A/en unknown
- 2017-12-09 BR BR112019011640-0A patent/BR112019011640B1/en active IP Right Grant
- 2017-12-09 DK DK17879353.5T patent/DK3551619T3/en active
- 2017-12-09 EP EP17879353.5A patent/EP3551619B1/en active Active
- 2017-12-09 EP EP24161243.1A patent/EP4364802A3/en active Pending
- 2017-12-09 FI FIEP17879353.5T patent/FI3551619T3/en active
- 2017-12-09 CA CA3046486A patent/CA3046486A1/en active Pending
- 2017-12-09 KR KR1020197017411A patent/KR102337138B1/en active IP Right Grant
- 2017-12-09 LT LTEPPCT/US2017/065482T patent/LT3551619T/en unknown
- 2017-12-09 WO PCT/US2017/065482 patent/WO2018107132A1/en active Application Filing
- 2017-12-09 IL IL297652A patent/IL297652A/en unknown
- 2017-12-09 CN CN201780078718.4A patent/CN110234636B/en active Active
- 2017-12-09 NZ NZ754751A patent/NZ754751A/en unknown
-
2019
- 2019-06-04 US US16/431,422 patent/US10584113B2/en active Active
- 2019-06-04 US US16/431,275 patent/US10584112B2/en active Active
- 2019-06-04 US US16/431,468 patent/US10759778B2/en active Active
- 2019-06-06 IL IL267172A patent/IL267172A/en unknown
- 2019-06-18 ZA ZA2019/03928A patent/ZA201903928B/en unknown
- 2019-09-20 US US16/577,946 patent/US11021460B2/en active Active
- 2019-09-20 US US16/577,876 patent/US11021459B2/en active Active
- 2019-09-30 US US16/588,914 patent/US10954212B2/en active Active
-
2020
- 2020-02-18 US US16/793,923 patent/US10858341B2/en active Active
- 2020-02-18 US US16/794,170 patent/US10954213B2/en active Active
- 2020-09-24 AU AU2020239746A patent/AU2020239746B2/en active Active
- 2020-12-08 US US17/115,425 patent/US11505537B2/en active Active
-
2021
- 2021-04-26 US US17/240,181 patent/US20210253552A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256726A1 (en) | Carrier-binding agent compositions and methods of making and using the same | |
HUE053737T2 (en) | Pyridopyrroloquinoxaline compounds, their compositions and uses | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
GB2561629B (en) | Methods, Compositions and uses relating thereto | |
ZA201903928B (en) | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | |
GB2560212B (en) | Methods, compositions and uses relating thereto | |
GB2554485B (en) | Methods, compositions and uses relating thereto | |
GB201513020D0 (en) | Radiation-curable compositions, membranes and the manufacture and use of such membranes | |
GB201608762D0 (en) | Compositions and uses thereof | |
HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
GB2577456B (en) | Methods, compositions and uses relating thereto | |
GB2560213B (en) | Methods, compositions and uses relating thereto | |
GB2559645B (en) | Methods, compositions and uses relating thereto | |
GB201715799D0 (en) | Methods, compositions and uses relating thereto | |
GB201614897D0 (en) | Compositions and uses thereof | |
GB201602409D0 (en) | Compositions and uses thereof | |
GB201616678D0 (en) | Methods, compositions and uses relating thereto | |
GB201616676D0 (en) | Methods, compositions and uses relating thereto | |
GB201616745D0 (en) | Methods, compositions and uses relating thereto | |
GB201616746D0 (en) | Methods, compositions and uses relating thereto | |
GB201616645D0 (en) | Methods, compositions and uses relating thereto | |
GB201616753D0 (en) | Methods, compositions and uses relating thereto | |
GB201616647D0 (en) | Methods, compositions and uses relating thereto | |
GB201616648D0 (en) | Methods, compositions and uses relating thereto | |
GB201602404D0 (en) | Compositions and uses thereof |